Mackay Shields LLC Global Blood Therapeutics, Inc. Transaction History

Mackay Shields LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 04, 2020	SELL	$52.76 - $74.49 $696,432 - $983,267	-13,200 Closed	0 $0
Q2 2020 Jul 31, 2020	SELL	$48.73 - $81.82 $1.22 Million - $2.05 Million	-25,037 Reduced 65.48%	13,200 $834,000
Q1 2020 May 08, 2020	SELL	$41.72 - $87.2 $166,880 - $348,800	-4,000 Reduced 9.47%	38,237 $1.95 Million
Q4 2019 Feb 11, 2020	SELL	$45.7 - $81.86 $109,680 - $196,464	-2,400 Reduced 5.38%	42,237 $3.36 Million
Q3 2019 Nov 01, 2019	BUY	$45.35 - $57.91 $54,420 - $69,492	1,200 Added 2.76%	44,637 $2.17 Million
Q2 2019 Aug 13, 2019	BUY	$52.6 - $63.29 $1.45 Million - $1.74 Million	27,554 Added 173.48%	43,437 $2.29 Million
Q1 2019 May 13, 2019	SELL	$39.99 - $53.48 $23,994 - $32,087	-600 Reduced 3.64%	15,883 $840,000
Q4 2018 Feb 14, 2019	SELL	$31.54 - $46.67 $54,154 - $80,132	-1,717 Reduced 9.43%	16,483 $677,000
Q3 2018 Nov 14, 2018	BUY	$38.0 - $51.1 $95,000 - $127,750	2,500 Added 15.92%	18,200 $692,000
Q2 2018 Aug 06, 2018	BUY	$38.7 - $50.15 $23,220 - $30,090	600 Added 3.97%	15,700 $710,000
Q1 2018 May 03, 2018	BUY	$39.6 - $65.9 $597,960 - $995,090	15,100 New	15,100 $729,000

288K

Ticker GBT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,476,200
Market Cap $4.62B
Description
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses...

Get notified when there are updates to the investment portfolio of Mackay Shields LLC, based on Form 13F filings with the SEC.

Stay updated on Mackay Shields LLC with notifications on news.